Hormone replacement therapy in postmenopausal women: all the treatments are not the same;Traitement hormonal chez les femmes ménopausées : tous les traitements sont-ils équivalents ?

Gynecologie Obstetrique et Fertilite

Volumn 35, Issue 5, 2007, Pages 388-397

  Ribot, C ^a   Tremollieres F ^a  

^a Paul Sabatier University   (France)

Author keywords

Bio identical hormones; Breast cancer risk; Cardiovascular risk; Hormone replacement therapy (HRT); Menopause; Thromboembolic risk

Indexed keywords

ESTRADIOL; ESTROGEN DERIVATIVE; PROGESTERONE; PROGESTERONE DERIVATIVE; SEX HORMONE; GESTAGEN;

ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CORONARY ARTERY THROMBOSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; VENOUS THROMBOEMBOLISM; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; METHODOLOGY; MIDDLE AGED; REVIEW; RISK FACTOR; THROMBOSIS;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RISK FACTORS; THROMBOSIS;

EID: 34247573875     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2007.02.013     Document Type: Article

References (66)

1. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6,8 years of hormone therapy. JAMA 288 (2002) 49-57
2. Writing Group for the The Women's Health Initiative randomized controlled trial. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 1701-1712
3. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
4. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., and Lasser N.L. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349 (2003) 523-534
5. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J Womens's Health 15 (2006) 35-44
6. The Women's Health Initiative Steering Committee. Effects or conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
7. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114 (2005) 448-454
8. Moggs J.G., and Orphanides G. Estrogen receptors: orchestrators of pleiotropic responses. EMBO Rep. 21 (2001) 775-781
9. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Toxicol. Lett. 127 (2002) 217-224
10. Ennmark E., Pelto-Huikko M., Grandien K., Lagercrantz S., Lagercrantz J., Fried G., et al. Human estrogen receptor ß: gene structure, chromosomal localization and expression pattern. J. Clin. Endocrinol. Metab. 82 (1997) 4258-4265
11. Giangrande P.H., and McDonnell D.P. The A and B isoforms of the human progesterone receptor : two functionnally different transcription factors encoded by a single gene. Recent Prog. Horm. Res. 54 (1999) 291-313
12. Giangrande P.H., Kimbrel E.A., Edwards D.P., and McDonnell D.P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactors binding. Mol. Cell. Biol. 20 (2000) 3102-3115
13. Nilsson S., and Koehler K.F. Estrogen receptors and selective estrogen receptor modulators: molecular and cellular pharmacology. Basics Clin. Pharmacol. Toxicol. 96 (2005) 1-25
14. Lieveretz R.W. Pharmacology and pharmacokinetics of estrogens. Am. J. Obstet. Gynecol. 156 (1987) 1289-1293
15. Zhu B.T., and Conney A.H. Functionnal role of estrogen metabolism in target cells : review and perspectives. Carcinogenesis 19 (1998) 1-27
16. Jefcoate C.R., Liehr J., Santen R.J., Sutter T.R., Yager J.D., Yue W., et al. Tissue-specific synthesis and oxydative metabolism of estrogens. J. Natl. Cancer Inst. Monog. 27 (2000) 95-112
17. Tsuchiya Y., Nakajima M., and Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in humans. Cancer Lett. 227 (2005) 115-124
18. Masi L., Becherini L., Gennari L., Amadei A., Colli E., Falchetti A., et al. Polymorphism of the aromatase gene in postmenopausal italian women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab. 86 (2001) 2263-2269
19. Bulun S.E., Noble L.S., Takayama K., Michael M.D., Agarwal V., Fisher C., et al. Endocrine disorders associated with high aromatase expression. J. Steroid Biochem. Mol. Biol. 61 (1997) 133-139
20. Miyoshi Y., Ando A., Hasegawa S., Ishitobi M., Yamamura J., Irahara N., et al. Association of genetic polymorphisms in CPY19 and CPY1A1 with the estrogen-receptor positive breast cancer risk. Eur. J. Cancer 39 (2003) 2531-2537
21. Lepine J., Bernard O., Plante M., Têtu B., Pelletier G., Labrie F., et al. Specificty and selectivity of the conjugation of estradiol, estrone and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronyltransferases expressed in endometrium. J. Clin. Endocrinol. Metab. 89 (2004) 5222-5232
22. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy I., Higginbotham S., et al. Molecular origin of cancer: catechol-estrogen, 3,4 quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA 94 (1997) 10937-10942
23. Yue W., Santen R.J., Wang J.P., Li Y., Verderame M.F., Bocchinfuso W.P., et al. Genotoxic metabolites of estradiol in breast: potential mechanisms of estradiol induced carcinogenesis. J. Ster. Biochem. Mol. Biol. 86 (2003) 477-486
24. Russo J., and Russo I.H. Genotoxicity of steroidal estrogens. Trends Endocrinol. Metab. 15 (2004) 211-214
25. Cavalieri E.L., and Rogan E.G. A unifying mechanism in the initiation of cancer and other diseases by catechol-quinones. Ann. N. Y. Acad. Sci. 1028 (2004) 247-257
26. Dawling S., Hacchey D.L., Roodi N., and Parl F.F. In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4- hydroxyestriol. Chem. Res. Toxicol. 17 (2004) 1258-1264
27. Seeger H., Wallwiener D., Kraemer E., and Mueck A.O. Comparison of possible carcinogenic estradiol metabolites: effect on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 54 (2006) 74-77
28. Wiebe J.P., Muzia D., Hu J., Szwajcer D., Hill S.A., and Seachrist J.L. The 4-pregnene and 5α-progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res. 60 (2000) 936-943
29. Salmen T., Heikkinen A.M., Mahonen A., Kroger H., Komulanein M., Saarikoski S., et al. The protective effect of hormone replacement therapy on fracture risk is modulated by estrogen alpha receptor genotype in early postmenopausal women. J. Bone Miner. Res. 15 (2000) 2479-2486
30. Roper R.J., Griffith J.S., Lyttle C.R., Doerge R.W., McNabb A.W., Broadbent R.E., et al. Interactive quantitative trait loci control phenotypic variation in murine estradiol-regulated response. Endocrinology 140 (1999) 556-561
31. Peverill R.E. Hormone therapy and venous thromboembolism. Best Practice Res. Clin. Endocrinol. Metab. 17 (2003) 149-164
32. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized trial. JAMA 282 (1999) 637-645
33. Scarabin P.Y., Plu-Burau G., Bara L., Bonithon-Kopp C., Guize L., and Samama M.M. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb. Haemost. 70 (1993) 584-587
34. Scarabin P.Y., Alhenc-Gelas M., Plu-Burau G., Taisne P., Agher R., and Aiasch H. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3071-3078
35. Oger E., Alhenc-Gelas M., Lacut K., Blouch M.T., Roudaut N., Kerlan V., et al., SARAH Investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1671-1676
36. Scarabin P.Y., et al., for the ESTHER Study Group. Differential associations of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-431
37. Arnal J.F., Gourdy P., Elhage R., Garmy-Susini B., Delmas E., Brouchet L., et al. Estrogen and atherosclerosis. Eur. J. Endocrinol. 150 (2004) 113-117
38. Vehkavaara S., Silveira A., Hakala-Ala-Pietila T., Virkamaki A., Hovatta O., Hamsten A., et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85 (2001) 619-625
39. Wakatsuki A., Okatani Y., Ikenoue N., and Fukaya T. Different effects of oral conjucated equine estrogen and transdermal estrogen replacement therapy on size and oxydative susceptibility of low-density lipoprotein particles in. postmenopausal women. Circulation 106 (2002) 1771-1776
40. Vihma V., Vehkavaara S., Yki-Jarvinen H., Hohtari H., and Tikkanen M.J. Differential effects of oral and transdermal estradiol treatment on circulating estradiol fatty acid ester concentrations in postmenopausal women. J. Clin. Endocrinol. Metab. 88 (2003) 588-593
41. Vehkavaara S., Hakala-Ala-Pietila T., Virkamaki A., Bergholm R., Ehnholm C., Hovatta O., et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 102 (2000) 2687-2693
42. Post M.S., van der Mooren M.J., Stehouwer C.D., van Baal W.M., Mijatovik V., Schalkwijk C.G., et al. Effects of transdermal and oral estrogen replacement therapy on C-reactive protein levels in post-menopausal women: a randomized, placebo-controlled trial. Thromb. Haemost. 88 (2002) 605-610
43. Post M.S., Christella M., Thomassen L.G., van der Mooren M.J., van Baal W.M., Rosing J., et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1116-1121
44. Oger E., Alhenc-Gelas M., Lacut K., Blouch M.T., Roudaut N., Kerlan V., et al. SARAH investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity of activated protein C among postmenopausal women: a randomized trial. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1671-1676
45. Smolders R.G., Van der Mooren M.J., Teerlink T., Merkus J.M., Kroeks M.V., Franke H.R., et al. A randomized-placebo-controlled study of the effect of transdermal vs oral estradiol with or without gestodene on homocysteine levels. Fertil. Steril. 79 (2003) 261-267
46. Post M.S., Leurs J.R., van der Mooren M.J., van Baal W.M., Stehouwer C.D., and Kenemans P. Different effects of low-dose transdermal and oral estrogen replacement therapy on pro-carboxy-peptidase U, an inhibitor of fibrinolysis in healthy post-menopausal women : a randomized, placebo-controlled study. Thromb. Haemost. 93 (2005) 620-622
47. Post M.S., Rosing J., Thomassen L.G., Kenemans P., Bratt D.D., and Van der Mooren M.J. Less effects of intra-nasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. (2006) 27 (Epub ahead of print)
48. Lewandowski K.C., Komorowski J., Mikhalidis D.P., Bienkiewicz M., Tan B.K., Lewinski A., et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J. Clin. Endocrinol. Metab. 91 (2006) 3123-3130
49. Hemelaar M., Kenemans P., Schalwijk C.G., Braat D.D., and van der Mororen M.J. No increase in C-reactive protein during intra nasal compared to oral hormone therapy in healthy postmenopausal women. Hum. Reprod. 21 (2006) 1635-1642
50. Sumino H., Ichikawa S., Kasama S., Takahashi T., Kumakura H., Takayama Y., et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness ans vascular inflammatory markers in postmenopausal women. Atheroclerosis 189 (2006) 436-442
51. Bergkvist L., Adami H.O., Persson I., Hoover R., and Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N. Engl. J. Med. 321 (1989) 293-297
52. Santen R.J. Risk of breast cancer with progestins: critical assessment of current data. Steroids 68 (2003) 953-964
53. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., and Persson I. Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy. Int. J. Cancer 81 (1999) 339-344
54. Xu B., Kitawaki J., Koshiba H., Ishihara H., Kiyomizu M., Teramoto M., et al. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human brest cancer cells. Maturitas 56 (2007) 142-152
55. Wood C.E., Register T.C., Lees C.J., Chen H., Kimrey S., and Cline J.M. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Menopause (2007) (Epub ahead of print)
56. Nilsen J., and Brinton R.D. Divergent impact of progesterone and medroxxprogesterone acetate on nuclear mitogen activated protein kinase signaling. Proc. Natl. Acad. Sci. USA 100 (2003) 10506-10511
57. Cummings S.R., Duong T., Kenyon E., Cauley J.A., Whitehead M., Krueger K.A., et al., for the Multiples Outcomes Of Raloxifene Evaluation Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287 (2002) 216-220
58. Stefanick M.L., Anderson G.L., Margolis K.L., Hendrix S.L., Rodabough R.J., Paskett E.D., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
59. Zhang F., Chen Y., Pisha E., Shen L., Xiong Y., van Breemen R.B., et al. The major metabolite of equilin, 4-hydroxyequilin autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem. Res. Toxicol. 12 (1999) 204-213
60. Cuendet M., Liu X., Pisha E., Li Y., Yao J., Yu L., et al. Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A : differential gene expression. Mutat. Res. 55 (2004) 109-121
61. Mueck A.O., Seeger H., and Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 6 (2003) 211-217
62. Foidart J.M., Colin C., Denoo X., Desreux J., Beliard A., Fournier S., et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil. Steril. 69 (1998) 963-969
63. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92 (2000) 328-332
64. Porch J.V., Lee I.M., Cook N.R., Rexrode K.M., and Buring J.E. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 13 (2002) 847-854
65. Weiss L.K., Burkman R.T., Cushing-Haugen K.L., Voigt L.F., Simon M.S., Daling J.R., et al. Hormone replacement therapy regimens and breast cancer risk. Obstet. Gynecol. 100 (2002) 1148-1158
66. Olsson H.L., Ingvar C., and Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97 (2003) 1387-1392